# Tesamorelin References: Full Citation List — Research Digest

> Complete reference list for the Tesamorelin research digest. All citations from Phase II and III trials, pharmacokinetic studies, and meta-analyses with DOIs and PubMed links.

## All Citations

The following references are cited across this site. All Tesamorelin citations link to PubMed or the primary source; DOIs are provided where available.

[1] Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-70. DOI: 10.1056/NEJMoa072375. https://pubmed.ncbi.nlm.nih.gov/18057338/

[2] Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008;22(14):1719-28. DOI: 10.1097/QAD.0b013e32830a5058. https://pubmed.ncbi.nlm.nih.gov/18690162/

[3] Falutz J, Potvin D, Mamputu JC, Assaad H, Zoltowska M, Michaud SE, Berger D, Somero M, Moyle G, Brown S, Martorell C, Turner R, Grinspoon S. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010;53(3):311-22. DOI: 10.1097/QAI.0b013e3181cbdaff. https://pubmed.ncbi.nlm.nih.gov/20101189/

[4] Stanley TL, Falutz J, Marsolais C, Morin J, Soulban G, Mamputu JC, Assaad H, Turner R, Grinspoon SK. Reduction in Visceral Adiposity Is Associated With an Improved Metabolic Profile in HIV-Infected Patients Receiving Tesamorelin. Clin Infect Dis. 2012;54(11):1642-1651. DOI: 10.1093/cid/cis251. https://pubmed.ncbi.nlm.nih.gov/22495074/

[5] Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effect of Tesamorelin on Liver Fat and Visceral Fat in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Clinical Trial. JAMA. 2014;312(4):380-389. DOI: 10.1001/jama.2014.8334. https://pubmed.ncbi.nlm.nih.gov/25038357/

[6] Stanley TL, Fourman LT, Feldpausch MN, Purdy J, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821-e830. DOI: 10.1016/S2352-3018(19)30338-8. https://pubmed.ncbi.nlm.nih.gov/31611038/

[7] Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-9. DOI: 10.1001/archneurol.2012.1970. https://pubmed.ncbi.nlm.nih.gov/22869065/

[8] Ellis RJ, Vaida F, Hu K, Dube M, Henry B, Chow F, Heaton RK, Lee D, Sattler F. Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity. J Infect Dis. 2025;231(5):1230-1238. DOI: 10.1093/infdis/jiaf012. https://pubmed.ncbi.nlm.nih.gov/39813152/

[9] González-Sales M, Barrière O, Tremblay PO, Nekka F, Mamputu JC, Boudreault S, Tanguay M. Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects. Clin Pharmacokinet. 2015;54(3):285-94. DOI: 10.1007/s40262-014-0202-x. https://pubmed.ncbi.nlm.nih.gov/25358450/

[10] Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a Growth Hormone-Releasing Hormone Analog on Endogenous GH Pulsatility and Insulin Sensitivity in Healthy Men. J Clin Endocrinol Metab. 2011;96(1):150-158. DOI: 10.1210/jc.2010-1587. https://pubmed.ncbi.nlm.nih.gov/20943777/

[11] Clemmons DR, Miller S, Mamputu JC. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PLoS One. 2017;12(6). DOI: 10.1371/journal.pone.0179538. https://pubmed.ncbi.nlm.nih.gov/28617838/

[12] Fourman LT, Billingsley JM, Agyapong G, Ho Sui SJ, Feldpausch MN, Purdy J, Zheng I, Pan CS, Corey KE, Torriani M, Kleiner DE, Hadigan CM, Stanley TL, Chung RT, Grinspoon SK. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight. 2020;5(16). DOI: 10.1172/jci.insight.140134. https://pubmed.ncbi.nlm.nih.gov/32701508/

[13] Stanley TL, Falutz J, Mamputu JC, Soulban G, Potvin D, Grinspoon SK. Effects of Tesamorelin on Inflammatory Markers in HIV Patients with Excess Abdominal Fat: Relationship with Visceral Adipose Reduction. AIDS. 2011;25(10):1281-1288. DOI: 10.1097/QAD.0b013e328347f3f1. https://pubmed.ncbi.nlm.nih.gov/21516030/

[14] Lake JE, La K, Erlandson KM, Adrian S, Yenokyan G, Scherzinger A, Dubé MP, Stanley T, Grinspoon S, Falutz J, Mamputu JC, Marsolais C, McComsey GA, Brown TT. Tesamorelin improves fat quality independent of changes in fat quantity. AIDS. 2021;35(9):1395-1402. DOI: 10.1097/QAD.0000000000002897. https://pubmed.ncbi.nlm.nih.gov/33756511/

[15] Mangili A, Falutz J, Mamputu JC, Stepanians M, Hayward B. Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat. PLoS One. 2015;10(10). DOI: 10.1371/journal.pone.0140358. https://pubmed.ncbi.nlm.nih.gov/26457580/

[16] Rousakis A, et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026;20(1):2-12. DOI: 10.1016/j.orcp.2026.01.002. https://pubmed.ncbi.nlm.nih.gov/41545261/

[17] Fourman LT, et al. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS. 2024. DOI: 10.1097/QAD.0000000000003965. https://pmc.ncbi.nlm.nih.gov/articles/PMC11365754/

[18] Rahman F, McLaughlin T, Mesquita P, Morin J, Potvin D, De Chantal M, Aberg JA. Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial. J Clin Transl Sci. 2022;7(1):e40. DOI: 10.1017/cts.2022.515. https://pubmed.ncbi.nlm.nih.gov/36845310/

[19] National Institute of Diabetes and Digestive and Kidney Diseases. Tesamorelin — LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. NCBI Bookshelf (NIH/LiverTox). 2020. https://www.ncbi.nlm.nih.gov/books/NBK548730/

[20] Fourman LT, et al. Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV. AIDS. 2017;31(16). DOI: 10.1097/QAD.0000000000001614. https://pubmed.ncbi.nlm.nih.gov/28832410/

---

A peer-reviewed field record of the tesamorelin literature — FDA approvals, Phase III trials, and pharmacokinetics indexed here, not prescribed here.